GGrantIndex
← Leaderboards

Harriet L Robinson

Emory University

Google Scholar ↗PubMed ↗ORCID ↗
$13,479,393
Attributed
$13,479,393
Total exposure
31
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $6.1M · FY2005–17
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$52,251,509 · 34

By mechanism

U19$25,853,109 · 3
P01$18,978,986 · 5
P51$3,195,873 · 22
U01$1,859,000 · 1
R44$1,398,615 · 1
R01$676,285 · 1

Top collaborators

No co-investigators on record.

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Vaccine Development”

Research focus

Vaccine DevelopmentVaccinesResponseVirus-Like ParticleT-LymphocyteAdjuvantDna/Mva VaccinePreclinical StudyInfectionVirusMacaca MulattaClinical TrialsAfricaImmune ResponseVectorVector VaccineCountryAsiaGranulocyte-Macrophage Colony-Stimulating FactorSouth AfricaAcquired Immunodeficiency SyndromeCause Of DeathLeadershipIndia

Grant awards (66)

Enhancing protective antibody responses for a DNA/MVA HIV vaccine$658,159
R44 · FY2017 · AI · contact PI
Enhancing protective antibody responses for a DNA/MVA HIV vaccine$740,456
R44 · FY2016 · AI · contact PI
Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine$289,641
R43 · FY2014 · AI · contact PI
Project 1: Immunogens and Manufacturing$1,859,000
U01 · FY2012 · AI · contact PI
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines$4,352,253
U19 · FY2011 · AI · contact PI
Clinical Trials and Ancillary Assays$874,348
U19 · FY2011 · AI · contact PI
Administrative Core$614,447
U19 · FY2011 · AI · contact PI
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines$4,885,098
U19 · FY2010 · AI · contact PI
Clinical Trials and Ancillary Assays$745,000
U19 · FY2010 · AI · contact PI
Administrative Core$506,604
U19 · FY2010 · AI · contact PI
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines$4,736,301
U19 · FY2009 · AI · contact PI
Clinical Trials and Ancillary Assays$722,307
U19 · FY2009 · AI · contact PI
Administrative Core$491,176
U19 · FY2009 · AI · contact PI
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines$3,478,707
U19 · FY2008 · AI · contact PI
Clinical Trials and Ancillary Assays$447,902
U19 · FY2008 · AI · contact PI
Administrative Core$304,576
U19 · FY2008 · AI · contact PI
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES$81,625
P51 · FY2008 · RR · contact PI
GM-CSF-Adjuvanted Clade C DNA/MVA and MVA/MVA Vaccines$2,915,139
U19 · FY2007 · AI · contact PI
Clinical Trials and Ancillary Assays$437,192
U19 · FY2007 · AI · contact PI
Administrative Support$342,059
U19 · FY2007 · AI · contact PI
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES$104,725
P51 · FY2007 · RR · contact PI
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES$107,378
P51 · FY2006 · RR · contact PI
PROJECT 1: DNA AND MVA IMMUNOGENS$107,378
P51 · FY2006 · RR · contact PI
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES$107,378
P51 · FY2006 · RR · contact PI
DNA/MWA Immunogens, Cross-clade Immune Responses$1,688,283
P01 · FY2005 · AI
PROJECT 1: DNA IMMUNOGENS AND PRECLINICAL TRIALS$96,399
P51 · FY2005 · RR
PROJECT 1: DNA AND MVA IMMUNOGENS$96,399
P51 · FY2005 · RR
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES$96,399
P51 · FY2005 · RR
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES$96,399
P51 · FY2005 · RR
DNA/MWA Immunogens, Cross-clade Immune Responses$2,670,866
P01 · FY2004 · AI
PROJECT 1: DNA AND MVA IMMUNOGENS$95,071
P51 · FY2004 · RR
PROJECT 1: DNA IMMUNOGENS AND PRECLINICAL TRIALS$95,071
P51 · FY2004 · RR
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES$95,071
P51 · FY2004 · RR
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES$95,071
P51 · FY2004 · RR
BASIC PRINCIPALS OF DNA-BASED IMMUNIZATIONS$35,765
P51 · FY2004 · RR
DNA/MWA Immunogens, Cross-clade Immune Responses$3,892,120
P01 · FY2003 · AI
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES$1,119,409
P01 · FY2003 · AI
PROJECT 2 AND CORE A: PRECLINICAL TRIALS$87,166
P51 · FY2003 · RR
PROJECT 1: DNA AND MVA IMMUNOGENS$87,166
P51 · FY2003 · RR
DNA/MVA IMMUNOGENS, CROSS-CLADE RESPONSES$87,166
P51 · FY2003 · RR
PROJECT 1: DNA IMMUNOGENS AND PRECLINICAL TRIALS$87,166
P51 · FY2003 · RR
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES$87,166
P51 · FY2003 · RR
BASIC PRINCIPALS OF DNA-BASED IMMUNIZATIONS$31,173
P51 · FY2003 · RR
DNA/MWA Immunogens, Cross-clade Immune Responses$2,912,750
P01 · FY2002 · AI
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES$1,483,964
P01 · FY2002 · AI
SERIAL PATIENT ENVS AS TARGETS &STIMULATORS OF ANTIBODY$209,143
P51 · FY2002 · RR
HIV 1 IMMUNOGENICITY TRIAL$209,143
P51 · FY2002 · RR
HERPES B VACCINE DEVELOPMENT FOR RHESUS MACAQUES$209,143
P51 · FY2002 · RR
DNA &PROTEIN IMMUNOGENS FOR SIV &HIV VACCINES$209,143
P51 · FY2002 · RR
CDC MEASLES TRIAL$209,143
P51 · FY2002 · RR
BASIC PRINCIPLES OF TRANSFECTION INITIATED IMMUNIZATION$209,143
P51 · FY2002 · RR
DNA IMMUNOGENS AND MACAQUE TRIALS$159,181
P01 · FY2002 · AI
Preclinical trials$0
P01 · FY2002 · AI
Core--Central facility$0
P01 · FY2002 · AI
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES$1,637,982
P01 · FY2001 · AI
DNA/MWA Immunogens, Cross-clade Immune Responses$1,610,907
P01 · FY2001 · AI
BASIC PRINCIPLES OF TRANSFECTION INITIATED IMMUNIZATION$343,140
R01 · FY2001 · AI
DNA IMMUNOGENS AND MACAQUE TRIALS$159,181
P01 · FY2001 · AI
Core--Central facility$0
P01 · FY2001 · AI
Preclinical trials$0
P01 · FY2001 · AI
DNA AND PROTEIN IMMUNOGENS FOR SIV/HIV VACCINES$1,388,337
P01 · FY2000 · AI
BASIC PRINCIPLES OF TRANSFECTION INITIATED IMMUNIZATION$333,145
R01 · FY2000 · AI
DNA IMMUNOGENS AND MACAQUE TRIALS$256,006
P01 · FY2000 · AI
AIDS VACCINE DEVELOPMENT$84,459
P51 · FY2000 · RR
BASIC PRINCIPLES OF TRANSFECTION$39,712
P51 · FY2000 · RR
MEASLES VACCINE DEVELOPMENT$39,712
P51 · FY2000 · RR